𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose intravenous immunoglobulin in myasthenia gravis

✍ Scribed by A. Evoli; M. T. Palmisani; E. Bartoccioni; L. Padua; P. Tonali

Publisher
Springer Milan
Year
1993
Tongue
English
Weight
341 KB
Volume
14
Category
Article
ISSN
1590-1874

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Randomized, controlled trial of intraven
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis
✍ Gil I. Wolfe; Richard J. Barohn; Barbara M. Foster; Carlayne E. Jackson; John T. πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 80 KB

## Abstract We initiated a randomized, double‐blinded, placebo‐controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in

Immunoglobulin treatment in refractory m
Immunoglobulin treatment in refractory myasthenia gravis
✍ Anat Achiron; Yoram Barak; Shmuel Miron; Ida Sarova-Pinhas πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 134 KB πŸ‘ 2 views

Failure to induce and maintain remission in severe exacerbations of myasthenia gravis (MG), despite optimal care, is a common problem. We evaluated the efficacy and safety of high-dose intravenous immunoglobulin (IVIg) therapy in an open-label study of 10 patients with severe generalized myasthenia